Participated · Series A · Oct 2025

Expedition Therapeutics is developing next-generation oral small molecule therapies targeting inflammatory and respiratory diseases, with its lead program EXPD-101, a once-daily DPP1 inhibitor, currently in a global Phase 2 trial for COPD. The company reported that EXPD-101 was well tolerated in Phase 1 with no dose-limiting toxicities and showed dose-proportional pharmacokinetics supporting once-daily dosing. The first patient has been dosed in the Phase 2 COPD study, marking the company’s transition into mid-stage clinical development. Expedition combines translational expertise and clinical development experience with a platform for in-licensing global innovation. The recent $115 million Series B financing led by General Atlantic is intended to fund EXPD-101 through Phase 2, expand the company’s pipeline of therapies for inflammatory diseases, and further its research discovery efforts. Expedition is based in San Francisco and has announced board expansion tied to the financing.

Participated · Series C · May 2021

PathAI develops artificial intelligence-powered technology and an integrated platform for pathology aimed at improving diagnosis and treatment of diseases such as cancer. The company works with life sciences companies, researchers, pharmaceutical and diagnostic partners to advance precision medicine. PathAI plans to expand its product suite and commercial footprint to support the full lifecycle of drug development from translational research to global commercialization. It intends to develop AI-based pathology offerings for biopharma in disease indications beyond oncology and NASH. The company is also building a scalable workflow platform for CROs and reference lab partners to support broader deployments. PathAI emphasizes collaborations with pharmaceutical and diagnostic partners as part of its growth and product strategy. PathAI develops AI-powered technology and a platform intended to improve diagnostic accuracy and treatment efficacy for diseases such as cancer, using machine and deep learning. The company’s platform is applied to digital pathology and aims to advance pathology research and immuno-oncology development. With the new funding, PathAI plans to bolster and accelerate its clinical development capabilities and deepen partnerships with pharmaceutical companies. PathAI has worked strategically with industry partners to integrate insights from data into cancer therapy development. The company is headquartered in Boston and was founded in 2016. Including the latest financing, PathAI has raised a total of $90 million since its founding. PathAI is a Boston, MA-based provider of AI-powered technology for pathology research. Its platform uses machine and deep learning to improve diagnostic accuracy and treatment efficacy for diseases such as cancer. The company provides AI-powered research tools and services and works with leading life sciences companies and researchers to advance precision medicine. PathAI intends to use the funds from the LabCorp investment to expand clinical development of its AI-enabled computational pathology and to advance integration with clinical laboratories. The company is led by co-founder and CEO Andy Beck, M.D., Ph.D. Financially, LabCorp's strategic investment amount was not disclosed and follows a $60M round announced the prior month led by General Atlantic and General Catalyst. PathAI develops AI-powered technology and a flagship pathology research platform intended to improve the accuracy, reproducibility, and sub-typing of disease diagnoses such as cancer. The company works with leading life sciences firms and diagnostic laboratories to accelerate drug development and deliver faster, more predictive diagnostics to patients. PathAI plans to use new capital to enhance offerings to existing partners, drive continuous improvement of its platform, meet market demand, and fund R&D into new tools and medical devices. The company has secured quality management and information security certifications and publicly noted partnerships with Bristol-Myers Squibb and Novartis. Staff headcount grew from 25 to more than 60 over the past year, reflecting investments in machine learning, product development, regulatory affairs, and scientific program management. Headquartered in Boston, PathAI emphasizes scaling its solutions globally to improve patient diagnosis and treatment.

Participated · Series C · Apr 2021

Arcellx is a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies. Its platform (ARC-SparX) underlies cell therapy candidates including CART-ddBCMA and ACLX-001/ACLX-002. CART-ddBCMA is a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 with a pivotal trial anticipated to begin in 2022. The company plans to use newly raised funds to develop CART-ddBCMA and to initiate clinical trials for ACLX-001 (multiple myeloma) and ACLX-002 (acute myelogenous leukemia). Financially, Arcellx completed a $115M Series C financing. The company is led by Chairman and CEO Rami Elghandour. Arcellx is a biopharmaceutical company developing an ARC-T + sparX intelligent cell therapy platform. The proprietary platform uses sparX soluble proteins to bind one or more tumor antigens and engage a universal receptor on engineered Antigen-Receptor Complex T cells (ARC-T), forming a sparX+ARC-T+tumor complex that mediates tumor killing. The company is advancing a pipeline that includes a bivalent BCMA-targeted ARC-T for multiple myeloma and a CD123-targeted therapy for acute myeloid leukemia, plus earlier-stage programs targeting solid tumors and diseases outside oncology. Arcellx positions the approach as improving safety and efficacy relative to conventional CAR-T therapies while broadening patient access and enabling scalable, efficient manufacturing. The company plans to begin clinical testing of its lead BCMA-targeted therapy in the coming months. Arcellx is based in Montgomery County, Maryland, and recently raised $85 million in a Series B to fund clinical and earlier-stage development.